Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry
Identifieur interne : 006C24 ( Main/Exploration ); précédent : 006C23; suivant : 006C25Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry
Auteurs : Zanfina Ademi [Australie] ; Christopher M. Reid [Australie] ; Bruce Hollingsworth [Australie] ; Johannes Stoelwinder [Australie] ; Gabriel Steg [France] ; Deepak L. Bhatt [États-Unis] ; Margarite Vale [Australie] ; Danny Liew [Australie]Source :
- Clinical therapeutics [ 0149-2918 ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Background: Although few cardiovascular registries report the costs of illness or cost-effectiveness of health interventions, such information is critical to inform the effective and cost-effective management of cardiovascular disease, particularly if drawn from population-based registries, which more accurately reflect clinical practice and follow up patients for much longer than clinical trials. Objective: The goal of this study was to estimate the cost-effectiveness of closing the statin "treatment gap" in the secondary prevention of coronary artery disease (CAD) in Australia. Methods: A decision analysis Markov model was developed with yearly cycles and the health states of alive or dead. Using data from the Australian Reduction of Atherothrombosis for Continued Health Registry, the model compared current statin coverage (82%) in the secondary prevention of CAD (the current group) with a hypothetical situation of 100% coverage (the improved group). The 18% gap was filled with use of generic statins. Data from a recent meta-analysis were used to estimate the benefits of statin use in terms of reducing recurrent cardiovascular events and death. Government reimbursement data from 2011 were used to calculate direct health care costs. The cost of the intervention to improve statin coverage was assumed to be $250 per person. Years of life lived and costs were discounted at 5% annually. All values are given in Australian dollars. Results: Among the 2058 subjects in the current group, the model estimated that there would be 106 nonfatal myocardial infractions, 68 nonfatal strokes, and 275 deaths over 5 years. In the improved group, all of whom took statins, the corresponding numbers were 101, 65, and 259, equating to numbers needed to treat of 426, 639, and 127, respectively. Over the 5 years, there would be 0.018 life-years gained (discounted) at a net cost of $546 (discounted) per person. These equated to an incremental cost-effectiveness ratio of $29,717 per life-year gained. Conclusion: The results suggest that for patients with CAD, maximizing coverage with statins, in line with evidence-based recommendations, represents a cost-effective means of secondary prevention.
Affiliations:
- Australie, France, États-Unis
- Massachusetts, Victoria (État), Île-de-France
- Melbourne, Paris
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001762
- to stream PascalFrancis, to step Curation: 004746
- to stream PascalFrancis, to step Checkpoint: 001C27
- to stream Main, to step Merge: 007078
- to stream Main, to step Curation: 006C24
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry</title><author><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Melbourne EpiCentre, Department of Medicine (RMH), University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Epidemiology and Preventive Medicine, Monash University</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Epidemiology and Preventive Medicine, Monash University</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Hollingsworth, Bruce" sort="Hollingsworth, Bruce" uniqKey="Hollingsworth B" first="Bruce" last="Hollingsworth">Bruce Hollingsworth</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre for Health Economics, Monash University</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Stoelwinder, Johannes" sort="Stoelwinder, Johannes" uniqKey="Stoelwinder J" first="Johannes" last="Stoelwinder">Johannes Stoelwinder</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Epidemiology and Preventive Medicine, Monash University</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Steg, Gabriel" sort="Steg, Gabriel" uniqKey="Steg G" first="Gabriel" last="Steg">Gabriel Steg</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>INSERM U-698, Université Paris 7, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>VA Boston Healthcare System, Brigham and Women's Hospital, Boston, and Harvard Medical School</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Vale, Margarite" sort="Vale, Margarite" uniqKey="Vale M" first="Margarite" last="Vale">Margarite Vale</name><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>St Vincent's Hospital, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>St Vincent's Hospital, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0004773</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 12-0004773 INIST</idno><idno type="RBID">Pascal:12-0004773</idno><idno type="wicri:Area/PascalFrancis/Corpus">001762</idno><idno type="wicri:Area/PascalFrancis/Curation">004746</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001C27</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001C27</idno><idno type="wicri:doubleKey">0149-2918:2011:Ademi Z:cost:effectiveness:of</idno><idno type="wicri:Area/Main/Merge">007078</idno><idno type="wicri:Area/Main/Curation">006C24</idno><idno type="wicri:Area/Main/Exploration">006C24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry</title><author><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Melbourne EpiCentre, Department of Medicine (RMH), University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Epidemiology and Preventive Medicine, Monash University</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Epidemiology and Preventive Medicine, Monash University</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Hollingsworth, Bruce" sort="Hollingsworth, Bruce" uniqKey="Hollingsworth B" first="Bruce" last="Hollingsworth">Bruce Hollingsworth</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre for Health Economics, Monash University</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Stoelwinder, Johannes" sort="Stoelwinder, Johannes" uniqKey="Stoelwinder J" first="Johannes" last="Stoelwinder">Johannes Stoelwinder</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Epidemiology and Preventive Medicine, Monash University</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Steg, Gabriel" sort="Steg, Gabriel" uniqKey="Steg G" first="Gabriel" last="Steg">Gabriel Steg</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>INSERM U-698, Université Paris 7, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>VA Boston Healthcare System, Brigham and Women's Hospital, Boston, and Harvard Medical School</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Vale, Margarite" sort="Vale, Margarite" uniqKey="Vale M" first="Margarite" last="Vale">Margarite Vale</name><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>St Vincent's Hospital, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>St Vincent's Hospital, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author></analytic><series><title level="j" type="main">Clinical therapeutics</title><title level="j" type="abbreviated">Clin. ther.</title><idno type="ISSN">0149-2918</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Clinical therapeutics</title><title level="j" type="abbreviated">Clin. ther.</title><idno type="ISSN">0149-2918</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ambulatory</term><term>Antilipemic agent</term><term>Australia</term><term>Coronary heart disease</term><term>Cost efficiency analysis</term><term>Health economy</term><term>Human</term><term>Register</term><term>Statin derivative</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Economie santé</term><term>Analyse coût efficacité</term><term>Dérivé de la statine</term><term>Australie</term><term>Homme</term><term>Ambulatoire</term><term>Registre</term><term>Cardiopathie coronaire</term><term>Hypolipémiant</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Australie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Although few cardiovascular registries report the costs of illness or cost-effectiveness of health interventions, such information is critical to inform the effective and cost-effective management of cardiovascular disease, particularly if drawn from population-based registries, which more accurately reflect clinical practice and follow up patients for much longer than clinical trials. Objective: The goal of this study was to estimate the cost-effectiveness of closing the statin "treatment gap" in the secondary prevention of coronary artery disease (CAD) in Australia. Methods: A decision analysis Markov model was developed with yearly cycles and the health states of alive or dead. Using data from the Australian Reduction of Atherothrombosis for Continued Health Registry, the model compared current statin coverage (82%) in the secondary prevention of CAD (the current group) with a hypothetical situation of 100% coverage (the improved group). The 18% gap was filled with use of generic statins. Data from a recent meta-analysis were used to estimate the benefits of statin use in terms of reducing recurrent cardiovascular events and death. Government reimbursement data from 2011 were used to calculate direct health care costs. The cost of the intervention to improve statin coverage was assumed to be $250 per person. Years of life lived and costs were discounted at 5% annually. All values are given in Australian dollars. Results: Among the 2058 subjects in the current group, the model estimated that there would be 106 nonfatal myocardial infractions, 68 nonfatal strokes, and 275 deaths over 5 years. In the improved group, all of whom took statins, the corresponding numbers were 101, 65, and 259, equating to numbers needed to treat of 426, 639, and 127, respectively. Over the 5 years, there would be 0.018 life-years gained (discounted) at a net cost of $546 (discounted) per person. These equated to an incremental cost-effectiveness ratio of $29,717 per life-year gained. Conclusion: The results suggest that for patients with CAD, maximizing coverage with statins, in line with evidence-based recommendations, represents a cost-effective means of secondary prevention.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>États-Unis</li></country><region><li>Massachusetts</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Melbourne</li><li>Paris</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name></region><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name><name sortKey="Hollingsworth, Bruce" sort="Hollingsworth, Bruce" uniqKey="Hollingsworth B" first="Bruce" last="Hollingsworth">Bruce Hollingsworth</name><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name><name sortKey="Stoelwinder, Johannes" sort="Stoelwinder, Johannes" uniqKey="Stoelwinder J" first="Johannes" last="Stoelwinder">Johannes Stoelwinder</name><name sortKey="Vale, Margarite" sort="Vale, Margarite" uniqKey="Vale M" first="Margarite" last="Vale">Margarite Vale</name></country><country name="France"><region name="Île-de-France"><name sortKey="Steg, Gabriel" sort="Steg, Gabriel" uniqKey="Steg G" first="Gabriel" last="Steg">Gabriel Steg</name></region></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006C24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006C24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0004773
|texte= Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry
}}
| This area was generated with Dilib version V0.6.33. |  |